Therapy Areas: Inflammatory Diseases
Soligenix expects US patent for Dusquetide related analogs in infectious disease and oral mucositis
5 April 2019 -

Biopharmaceutical company Soligenix Inc (Nasdaq:SNGX) revealed on Thursday that it expects to receive the patent from the US Patent Office titled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity" on 9 April 2019.

This new patent, which has been assigned the number #10,253,068, claims composition of matter for novel innate defence regulator (IDR) analogs, expanding patent protection to diverse analog structures. Therapeutic use claims in oral mucositis, colitis and infectious disease, both alone and in conjunction with antibiotics, will also issue.

According to the company, Dusquetide (the active ingredient in SGX942) is a novel, first-in-class IDR. It modulates the response of the innate immune system in response to various stimuli, including infection, tissue damage and inflammation. IDRs have no direct antibiotic activity but, by modulating the host's innate immune system responses, increase survival after infections caused by a broad range of bacterial Gram-negative and Gram-positive pathogens.

SGX942 demonstrated positive results in a Phase 2 study in the treatment of oral mucositis in head and neck cancer (HNC) patients. In addition to the oral mucositis findings, an increased incidence of "complete response" of tumour at the one-month and 12-month follow-up visits were observed. Decreases in infection rate and an increase in the 12-month survival rate were observed, stated the company.

Login
Username:

Password: